Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer.

Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer.

Item
http://www.wikidata.org/entity/Q33186647
Paclitaxel targets VEGF-mediated angiogenesis in ovarian cancer treatmentTransforming growth factor-β, insulin-like growth factor I/insulin-like growth factor I receptor and vascular endothelial growth factor-A: prognostic and predictive markers in triple-negative and non-triple-negative breast cancer.Osterix transcriptional factor is involved in the metastasis of human breast cancers.High vascular endothelial growth factor gene expression predicts poor outcome in patients with non-luminal A breast cancer.Potential tumorigenic programs associated with TP53 mutation status reveal role of VEGF pathwayPhase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumoursOverexpression of neuropilin-1 promotes constitutive MAPK signalling and chemoresistance in pancreatic cancer cellsAssociation of -2549 insertion/deletion polymorphism of vascular endothelial growth factor with breast cancer in North Indian patients.Yeast-derived beta-glucan augments the therapeutic efficacy mediated by anti-vascular endothelial growth factor monoclonal antibody in human carcinoma xenograft models.The role of vascular endothelial growth factor in the pathogenesis, diagnosis and treatment of malignant pleural effusionFunctional significance of VEGFR-2 on ovarian cancer cells.Turning tumor-promoting copper into an anti-cancer weapon via high-throughput chemistryEffect of antiangiogenic therapy on tumor growth, vasculature and kinase activity in basal- and luminal-like breast cancer xenografts.VEGFA links self-renewal and metastasis by inducing Sox2 to repress miR-452, driving Slug.
P2860

Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer.

Item
http://www.wikidata.org/entity/Q33186647
description
2003 nî lūn-bûn
@nan
2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Combined vascular endothelial ...... sitive advanced breast cancer.
@ast
Combined vascular endothelial ...... sitive advanced breast cancer.
@en
type
label
Combined vascular endothelial ...... sitive advanced breast cancer.
@ast
Combined vascular endothelial ...... sitive advanced breast cancer.
@en
prefLabel
Combined vascular endothelial ...... sitive advanced breast cancer.
@ast
Combined vascular endothelial ...... sitive advanced breast cancer.
@en
P1433
P1476
P2093
P304
P31
P407
P433
P478
P577
P698
P921
P1433
P1476
Combined vascular endothelial ...... ositive advanced breast cancer
@en
P2093
P304
P31
P407
P433
P478
P577
P698
P921